octanedioic acid adamantan-1-ylamide hydroxyamide | 827036-69-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: octanedioic acid adamantan-1-ylamide hydroxyamide
• 英文别名: N-(1-adamantyl)-N'-hydroxyoctanediamide
• CAS: 827036-69-1
• 化学式: C₁₈H₃₀N₂O₃
• 分子量: 322.448
• InChiKey: BKBWVGYLVWDHMZ-UHFFFAOYSA-N

物化性质

• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  7-(adamantan-1-yl-carbamoyl)-heptanoic acid methyl ester 在 酚酞 、 盐酸羟胺 、 sodium 、 溶剂黄146 作用下， 以 甲醇 、 水 为溶剂， 反应 24.0h， 以68%的产率得到octanedioic acid adamantan-1-ylamide hydroxyamide
  参考文献：
  名称：

  Histone deacetylase inhibitors and methods of use thereof

  摘要：

  这项发明提供了新型类别的HDAC抑制剂。还提供了一种使癌细胞对放疗的细胞毒作用敏感的方法，以及治疗癌症和治疗神经疾病的方法。此外，该发明还提供了包括该发明的HDAC抑制剂的药物组合物，以及包含一种HDAC抑制剂的容器的试剂盒。

  公开号：

  US20050014839A1

文献信息

• Histone Deacetylase Inhibitors and Methods of Use Thereof
  申请人：Kozikowski Alan P.

  公开号：US20110098504A1

  公开（公告）日：2011-04-28

  The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

  本发明提供了新型的HDAC抑制剂类。同时提供了一种使癌细胞对放疗的细胞毒性效应敏感的方法，以及治疗癌症和神经疾病的方法。此外，本发明还提供了包含本发明中的HDAC抑制剂的制药组合物，以及包含一个含有本发明中的HDAC抑制剂的容器的套装。
• A Series of Potent and Selective, Triazolylphenyl-Based Histone Deacetylases Inhibitors with Activity against Pancreatic Cancer Cells and <i>Plasmodium falciparum</i>
  作者：Yufeng Chen、Miriam Lopez-Sanchez、Doris N. Savoy、Daniel D. Billadeau、Geoffrey S. Dow、Alan P. Kozikowski

  DOI：10.1021/jm701606b

  日期：2008.6.1

  The discovery of the rules governing the inhibition of the various HDAC isoforms is likely to be key to identifying improved therapeutics that act as epigenetic modulators of gene transcription. Herein we present results on the modification of the CAP region of a set of triazolylphenyl-based HDACIs, and show that the nature of substitution on the phenyl ring plays a role in their selectivity for HDAC1 versus HDAC6, with low to moderate selectivity (2-51-fold) being achieved. In light of the valuable selectivity and potency that were identified for the triazolylphenyl ligand 6b in the inhibition of HDAC6 (IC50 = 1.9 nM), this compound represents a valuable research tool and a candidate for further chemical modifications. Lastly, these new HDACIs were studied for both their anticancer and antimalarial activity, which serve to validate the superior activity of the HDACI 10c.
• Histone deacetylase inhibitors and methods of use thereof
  申请人：Kozikowski P. Alan

  公开号：US20050032831A1

  公开（公告）日：2005-02-10

  One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

  这项发明的一个方面涉及HDAC抑制剂。还提供了一种使癌细胞对放疗的细胞毒作用敏感的方法。该发明还提供了治疗癌症和治疗神经疾病的方法。此外，该发明还提供了包含该发明的HDAC抑制剂的药物组合物，以及包含一个容器，其中含有该发明的HDAC抑制剂的试剂盒。